If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Lilly investigating Zepbound® (tirzepatide) for people with obstructive sleep apnea who do not have obesity?
Lilly does not have any studies planned investigating tirzepatide for people living with obstructive sleep apnea without obesity.
See important safety information, including boxed warning, in the attached prescribing information.
Obstructive Sleep Apnea Without Obesity
Obstructive sleep apnea (OSA) and obesity are 2 diseases that often overlap, with approximately 70% of the total amount of people diagnosed with OSA also living with obesity.1 Eli Lilly and Company does not have any studies planned investigating tirzepatide for people living with OSA without obesity.
Enclosed Prescribing Information
ZEPBOUND® (tirzepatide) injection, for subcutaneous use, Lilly
Reference
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1. Javaheri S, Barbe F, Campos-Rodriguez, F, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69(7):841-858. https://doi.org/10.1016/j.jacc.2016.11.069
Date of Last Review: December 20, 2024